跳至主要内容
临床试验/NL-OMON36943
NL-OMON36943已完成不适用

A Single-Center, Randomized, Investigator/Subject-Blind, Adaptive Single Ascending-Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including the Effect of Food), and Pharmacodynamics of RO5545965 Following Oral Administration in Healthy Subjects. - RO5545965 SAD and FE study

Hoffmann-La Roche0 个研究点目标入组 92 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
92

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Healthy male subjects
  • 18-45 yrs, inclusive
  • BMI 18 to 30 kg/m2, inclusive
  • Light smokers or non-smokers

排除标准

  • Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS.
  • Participation in another drug study within 90 days before screening, as calculated from the day of follow-up from the previous study.
  • Any donation of blood or significant blood loss within 3 months prior to first administration of the study drug.

研究者

相似试验